Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Marabelle A, et al. Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10. Lancet Oncol. 2020. PMID: 32919526 Clinical Trial.
Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.
Fabrizio D, Cristescu R, Albacker L, Snyder A, Ward A, Lunceford J, Aurora-Garg D, Jin F, Hopkins J, Rubin E, Hegde P. Fabrizio D, et al. Among authors: aurora garg d. Ann Oncol. 2021 Sep;32(9):1193-1194. doi: 10.1016/j.annonc.2021.05.805. Epub 2021 May 31. Ann Oncol. 2021. PMID: 34082018 Free article. No abstract available.
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
Lee KW, Van Cutsem E, Bang YJ, Fuchs CS, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Chao J, Wainberg ZA, Cao ZA, Aurora-Garg D, Kobie J, Cristescu R, Bhagia P, Shah S, Tabernero J, Shitara K, Wyrwicz L. Lee KW, et al. Among authors: aurora garg d. Clin Cancer Res. 2022 Aug 15;28(16):3489-3498. doi: 10.1158/1078-0432.CCR-22-0121. Clin Cancer Res. 2022. PMID: 35657979 Clinical Trial.
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.
Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. Mehra R, et al. Br J Cancer. 2018 Jul;119(2):153-159. doi: 10.1038/s41416-018-0131-9. Epub 2018 Jun 29. Br J Cancer. 2018. PMID: 29955135 Free PMC article. Clinical Trial.
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.
Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Caglevic C, Chung HC, Muro K, Van Cutsem E, Kobie J, Cristescu R, Aurora-Garg D, Lu J, Shih CS, Adelberg D, Cao ZA, Fuchs CS. Shitara K, et al. Among authors: aurora garg d. Ann Oncol. 2021 Sep;32(9):1127-1136. doi: 10.1016/j.annonc.2021.05.803. Epub 2021 May 31. Ann Oncol. 2021. PMID: 34082019 Free article. Clinical Trial.
Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.
Wei B, Kang J, Kibukawa M, Arreaza G, Maguire M, Chen L, Qiu P, Lang L, Aurora-Garg D, Cristescu R, Levitan D. Wei B, et al. Among authors: aurora garg d. J Mol Diagn. 2022 Jun;24(6):600-608. doi: 10.1016/j.jmoldx.2022.01.008. Epub 2022 Feb 24. J Mol Diagn. 2022. PMID: 35218944 Free article.
13 results